Drugs / silicon phthalocyanine 4
silicon phthalocyanine 4
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01800838 | Apr 2013 → Sep 2014 | mycosis fungoides and variants, primary cutaneous T-cell non-Hodgkin lymphoma | Kevin Cooper MD | Completed | No outcome recorded |
| Phase 1 | NCT00103246 | Sep 2004 → Dec 2008 | lymphoma, precancerous condition, skin carcinoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00023790 | Aug 2001 → Dec 2005 | breast cancer, head and neck cancer, lymphoma, metastatic malignant neoplasm +2 | Case Comprehensive Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | silicon phthalocyanine 4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00103246 ↗ |
| Known as | Pc 4 | “Patients receive silicon phthalocyanine 4 (Pc 4) IV over 2 hours on day 1 followed by light therapy over 30-60 minutes on day 2.” NCT00023790 ↗ |
| Known as | Pc-4 (Silicone phthalocyanine) | “Pc-4 (Silicone phthalocyanine)” NCT00023790 ↗1“Pc-4 (Silicone phthalocyanine)” NCT01800838 ↗ |
| Route | Intravenous | “silicon phthalocyanine 4 (Pc 4) IV over 2 hours” NCT00023790 ↗ |